Patents by Inventor Thomas F. Kenney

Thomas F. Kenney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Wake up receiver frame
    Patent number: 11974227
    Abstract: This disclosure describes systems, methods, and devices related to wake up receiver (WUR) frequency division multiple access (FDMA) transmission. A device may cause to send a wake up receiver (WUR) beacon frame on a WUR beacon operating channel to one or more station devices. The device may determine a first wake-up frame to be sent on a first WUR operating channel, wherein the first WUR operating channel is associated with one or more frequency division multiple access (FDMA) channels used for transmitting one or more wake-up frames to the one or more station devices. The device may determine to apply padding to the first wake-up frame based on a field included in a header of the first wake-up frame. The device may cause to send the first wake-up frame to a first station device of the one or more station devices.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: April 30, 2024
    Assignee: Intel Corporation
    Inventors: Po-Kai Huang, Shahrnaz Azizi, Daniel F. Bravo, Thomas J. Kenney, Vinod Kristem, Noam Ginsburg
  • Combination MCL-1 inhibitors with anti-cancer agents
    Patent number: 11957693
    Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: April 16, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • Combination MCL-1 inhibitors with anti-body drug conjugates
    Patent number: 11931424
    Abstract: The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: March 19, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • COMBINATION MCL-1 INHIBITORS WITH ANTI-CANCER AGENTS
    Publication number: 20230015985
    Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.
    Type: Application
    Filed: June 9, 2022
    Publication date: January 19, 2023
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • COMBINATION MCL-1 INHIBITORS WITH ANTI-BODY DRUG CONJUGATES
    Publication number: 20220409736
    Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate.
    Type: Application
    Filed: June 9, 2022
    Publication date: December 29, 2022
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER
    Publication number: 20180133212
    Abstract: Provided herein are methods and compositions for the treatment of cancer. In particular, the methods include administration of a Bcl-2 inhibitor and a BET inhibitor.
    Type: Application
    Filed: October 23, 2017
    Publication date: May 17, 2018
    Inventors: Jamie Geier Bates, Astrid Clarke, Thomas F. Kenney, Saritha Kusam, Stacey Tannheimer